228 related articles for article (PubMed ID: 27172899)
1. Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo.
Karpel-Massler G; Ramani D; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2016 Jun; 7(23):33512-28. PubMed ID: 27172899
[TBL] [Abstract][Full Text] [Related]
2. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
[TBL] [Abstract][Full Text] [Related]
3. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo.
Karpel-Massler G; Banu MA; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2016 Mar; 7(11):12791-805. PubMed ID: 26872380
[TBL] [Abstract][Full Text] [Related]
5. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis.
Hlavac M; Dwucet A; Kast RE; Engelke J; Westhoff MA; Siegelin MD; Debatin KM; Wirtz CR; Halatsch ME; Karpel-Massler G
Cell Oncol (Dordr); 2019 Jun; 42(3):287-301. PubMed ID: 30859392
[TBL] [Abstract][Full Text] [Related]
7. A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.
Karpel-Massler G; Horst BA; Shu C; Chau L; Tsujiuchi T; Bruce JN; Canoll P; Greene LA; Angelastro JM; Siegelin MD
Clin Cancer Res; 2016 Sep; 22(18):4698-711. PubMed ID: 27126996
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.
Zhang Y; Ishida CT; Shu C; Kleiner G; Sanchez-Quintero MJ; Bianchetti E; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 May; 8(1):7373. PubMed ID: 29743557
[TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo.
Karpel-Massler G; Shu C; Chau L; Banu M; Halatsch ME; Westhoff MA; Ramirez Y; Ross AH; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2015 Jun; 6(16):14507-21. PubMed ID: 26008975
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.
Karpel-Massler G; Ishida CT; Bianchetti E; Shu C; Perez-Lorenzo R; Horst B; Banu M; Roth KA; Bruce JN; Canoll P; Altieri DC; Siegelin MD
Cancer Res; 2017 Jul; 77(13):3513-3526. PubMed ID: 28522750
[TBL] [Abstract][Full Text] [Related]
11. Bcl-xL inhibition - a novel strategy for glioma therapy.
Karpel-Massler G; Siegelin MD
Aging (Albany NY); 2016 Sep; 8(9):1830-1831. PubMed ID: 27687793
[No Abstract] [Full Text] [Related]
12. Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma.
Halatsch ME; Kast RE; Dwucet A; Hlavac M; Heiland T; Westhoff MA; Debatin KM; Wirtz CR; Siegelin MD; Karpel-Massler G
Br J Pharmacol; 2019 Sep; 176(18):3681-3694. PubMed ID: 31222722
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.
Tagscherer KE; Fassl A; Campos B; Farhadi M; Kraemer A; Böck BC; Macher-Goeppinger S; Radlwimmer B; Wiestler OD; Herold-Mende C; Roth W
Oncogene; 2008 Nov; 27(52):6646-56. PubMed ID: 18663354
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
Karpel-Massler G; Pareja F; Aimé P; Shu C; Chau L; Westhoff MA; Halatsch ME; Crary JF; Canoll P; Siegelin MD
PLoS One; 2014; 9(12):e114583. PubMed ID: 25531448
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis.
Murphy ÁC; Weyhenmeyer B; Noonan J; Kilbride SM; Schimansky S; Loh KP; Kögel D; Letai AG; Prehn JH; Murphy BM
Apoptosis; 2014 Apr; 19(4):629-42. PubMed ID: 24213561
[TBL] [Abstract][Full Text] [Related]
16. Alantolactone induces apoptosis in glioblastoma cells via GSH depletion, ROS generation, and mitochondrial dysfunction.
Khan M; Yi F; Rasul A; Li T; Wang N; Gao H; Gao R; Ma T
IUBMB Life; 2012 Sep; 64(9):783-94. PubMed ID: 22837216
[TBL] [Abstract][Full Text] [Related]
17. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma.
Ishida CT; Shu C; Halatsch ME; Westhoff MA; Altieri DC; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 Jun; 8(23):37140-37153. PubMed ID: 28415755
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
20. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
